Aileron Therapeutics Stock Forecast, Price & News

Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALRN shares have increased by 165.4% and is now trading at $1.07.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aileron Therapeutics.

Wall Street analysts have given Aileron Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aileron Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Aileron Therapeutics.

Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings data on Tuesday, November, 17th. The company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.13).
View Aileron Therapeutics' earnings history.

3 analysts have issued 1-year price objectives for Aileron Therapeutics' stock. Their forecasts range from $2.00 to $5.00. On average, they expect Aileron Therapeutics' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 227.1% from the stock's current price.
View analysts' price targets for Aileron Therapeutics.

Aileron Therapeutics saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 946,200 shares, an increase of 25.1% from the September 30th total of 756,500 shares. Based on an average trading volume of 1,090,000 shares, the short-interest ratio is currently 0.9 days. Currently, 4.1% of the shares of the stock are short sold.
View Aileron Therapeutics' Short Interest.

Some companies that are related to Aileron Therapeutics include Rezolute (RZLTD), Minerva Neurosciences (NERV), Checkpoint Therapeutics (CKPT), 9 Meters Biopharma (NMTR), Sierra Oncology (SRRA), Taiwan Liposome (TLC), Tiziana Life Sciences (TLSA), Biofrontera (BFRA), Matinas BioPharma (MTNB), ContraFect (CFRX), Ritter Pharmaceuticals (RTTR), Ampio Pharmaceuticals (AMPE), LifeVantage (LFVN), Kindred Biosciences (KIN) and AVEO Pharmaceuticals (AVEO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV).

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Aileron Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (0.10%) and Wedbush Securities Inc. (0.09%). Company insiders that own Aileron Therapeutics stock include Bioventures Ltd Novartis, Jeffrey Allen Bailey, Kathryn Gregory, Reinhard J Ambros, Rickenbach Josef H Von and Vojo Vukovic.
View institutional ownership trends for Aileron Therapeutics.

ALRN stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and Wedbush Securities Inc.. Company insiders that have bought Aileron Therapeutics stock in the last two years include Jeffrey Allen Bailey, Kathryn Gregory, Reinhard J Ambros, Rickenbach Josef H Von, and Vojo Vukovic.
View insider buying and selling activity for Aileron Therapeutics.

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALRN stock can currently be purchased for approximately $1.07.

Aileron Therapeutics has a market capitalization of $43.54 million. The company earns $-29,370,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Aileron Therapeutics employs 13 workers across the globe.

The official website for Aileron Therapeutics is www.aileronrx.com.

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]